Celldex Therapeutics Inc [CLDX] stock prices are down -2.19% to $23.72 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLDX shares have gain 1.98% over the last week, with a monthly amount drifted -13.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on October 21, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $48. Previously, Barclays started tracking the stock with Underweight rating on October 13, 2025, and set its price target to $25. On April 28, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $64 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $46 on March 20, 2025. UBS initiated its recommendation with a Buy and recommended $44 as its price target on February 13, 2025. Citigroup started tracking with a Buy rating for this stock on October 07, 2024, and assigned it a price target of $70. In a note dated September 30, 2024, Goldman initiated an Neutral rating and provided a target price of $45 on this stock.
The stock price of Celldex Therapeutics Inc [CLDX] has been fluctuating between $14.40 and $29.05 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $23.72 at the most recent close of the market. An investor can expect a potential drop of -11.47% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
The Celldex Therapeutics Inc [NASDAQ:CLDX] reported sales of 2.60M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -40.54%, Pretax Profit Margin comes in at -34.47%, and Net Profit Margin reading is -34.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.28 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.35 points at the first support level, and at 22.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.36, and for the 2nd resistance point, it is at 25.01.
Ratios To Look Out For
It’s worth pointing out that Celldex Therapeutics Inc [NASDAQ:CLDX]’s Current Ratio is 13.01. Also, the Quick Ratio is 13.01, while the Cash Ratio stands at 0.7. Considering the valuation of this stock, the price to sales ratio is 606.22, the price to book ratio is 2.63.
Transactions by insiders
Recent insider trading involved RICHARD M WRIGHT, Officer, that happened on Nov 13 ’25 when 49298.0 shares were purchased. SVP & GENERAL COUNSEL, Jimenez Freddy A. completed a deal on Aug 13 ’25 to sell 771.0 shares.
